KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EPS (Weighted Average and Diluted) (2019 - 2025)

Historic EPS (Weighted Average and Diluted) for Novavax (NVAX) over the last 7 years, with Q3 2025 value amounting to -$1.25.

  • Novavax's EPS (Weighted Average and Diluted) fell 6447.37% to -$1.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.78, marking a year-over-year increase of 17772.93%. This contributed to the annual value of -$1.23 for FY2024, which is 7722.72% up from last year.
  • Per Novavax's latest filing, its EPS (Weighted Average and Diluted) stood at -$1.25 for Q3 2025, which was down 6447.37% from $0.6 recorded in Q2 2025.
  • Novavax's EPS (Weighted Average and Diluted)'s 5-year high stood at $2.93 during Q1 2025, with a 5-year trough of -$11.31 in Q4 2021.
  • In the last 5 years, Novavax's EPS (Weighted Average and Diluted) had a median value of -$1.26 in 2023 and averaged -$1.94.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first crashed by 148448.69% in 2021, then skyrocketed by 37904.76% in 2025.
  • Novavax's EPS (Weighted Average and Diluted) (Quarter) stood at -$11.31 in 2021, then soared by 79.75% to -$2.29 in 2022, then rose by 22.69% to -$1.77 in 2023, then soared by 69.92% to -$0.53 in 2024, then crashed by 134.77% to -$1.25 in 2025.
  • Its last three reported values are -$1.25 in Q3 2025, $0.6 for Q2 2025, and $2.93 during Q1 2025.